当前位置: X-MOL 学术Clin. Exp. Allergy › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
INEXAS: A Phase 2 Randomised Trial of On‐Demand Inhaled Interferon Beta‐1a in Severe Asthmatics
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2020-11-03 , DOI: 10.1111/cea.13765
Christopher McCrae 1, 2 , Marita Olsson 3 , Per Gustafson 4 , Anna Malmgren 5 , Malin Aurell 6 , Malin Fagerås 4 , Carla A Da Silva 6 , Anders Cavallin 7 , Jonathan Paraskos 8 , Karin Karlsson 7 , Cecilia Wingren 1 , Phillip Monk 9 , Richard Marsden 9 , Tim Harrison 10
Affiliation  

BACKGROUND Upper respiratory tract infections (URTI) are important triggers for asthma exacerbations. We hypothesised that inhalation of the anti-viral cytokine, interferon (IFN)-β, during URTI, could prevent these exacerbations.

中文翻译:


INEXAS:按需吸入干扰素 Beta-1a 治疗严重哮喘的 2 期随机试验



背景技术上呼吸道感染(URTI)是哮喘恶化的重要触发因素。我们假设,在 URTI 期间吸入抗病毒细胞因子干扰素 (IFN)-β 可以预防这些病情恶化。
更新日期:2020-11-03
down
wechat
bug